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ORIGINAL ARTICLE – ENDOCRINE TUMORS
Eucalcemic Parathyroid Hormone Elevation After
Parathyroidectomy for Primary Sporadic Hyperparathyroidism:
Risk Factors, Trend, and Outcome
Brian Hung-Hin Lang, MS, FRACS, Ian Yu-Hong Wong, MBBS, MRCS, Kai Pun Wong, MBBS, MRCS,
and Chung-Yau Lo, MS, FRCS, FACS
Department of Surgery, The University of Hong Kong, Hong Kong SAR, China
ABSTRACT
Background. Patients with eucalcemic parathyroid hor-
mone elevation (ePTH) after parathyroidectomy for
primary hyperparathyroidism (HPT) may be at risk of
recurrence. We aimed to examine risk factors, trend of
PTH level, and outcome of patients with ePTH 6 months
after parathyroidectomy.
Methods. A total of 161 primary HPT were analyzed. The
6-month postoperative calcium and PTH levels were
obtained. ePTH was defined as an elevated PTH level in
the presence of normocalcemia. At 6 months, 98 had
eucalcemic normal PTH and 63 (39.1%) had ePTH. Peri-
operative variables, PTH trend, and outcome were
compared between 2 groups. Multivariable analyses were
performed to identify independent preoperative and oper-
ative/postoperative risk factors for ePTH.
Results. Among preoperative factors, advanced age (odds
ratio [OR] = 1.042, P = .027) and low 25-hydroxyvitamin
D3 (25OHD3) (OR = 1.043, P = .009) were indepen-
dently associated with ePTH, whereas among operative/
postoperative factors, high 10-min intraoperative PTH
level (OR = 1.015, P = .040) and high postoperative
3-month PTH (OR = 1.048, P \ .001) were independently
associated with ePTH. After a mean follow-up of
38.7 months, recurrence rate was similar between the 2
groups (P = 1.00). In the first 2 postoperative years, 75
(46.6%) had ePTH on at least 1 occasion and 8 (5.0%) had
persistently ePTH on every occasion.
Conclusions. Advanced age, low 25OHD3, high 10-min
intraoperative PTH, and high postoperative 3-month PTH
were independently associated with ePTH at 6-month.
Although 39.1% of patients had ePTH at 6 months, more
than 50% had at least 1 ePTH within the first 2 years of
follow-up. Recurrence appeared similar between those with
or without ePTH at 6 months.
Although primary hyperparathyroidism (pHPT) remains
a relatively uncommon endocrine disease among Asian
countries with an incidence ranging between 0.5 and 1 per
3000 of the general population, it has been increasing over
the last decade.1–3 This is related to better patient educa-
tion, increased disease awareness, and more frequent serum
calcium screening.2,3 Similar to the West, parathyroidec-
tomy proves to be a cost-effective and curative treatment
for the majority pHPT patients.4 In experienced hands, the
surgical cure rate approaches 95%–100% with minimal
morbidity.4 However, despite attaining postoperative
normocalcemia, parathyroid hormone (PTH) elevation is
not uncommonly observed after surgery. In the literature,
this phenomenon of eucalcemic parathyroid hormone ele-
vation (ePTH) has been well described and studied,
although the exact etiology remains poorly understood.5 A
number of explanations or causes have been suggested, and
they include relative postoperative hypocalcemia/vitamin
D deficiency leading to secondary HPT, chronic renal
impairment, renal leak of calcium, bone remineralization or
bone hunger, changes in the calcium-sensing receptors,
decreased vitamin D 1-alpha-hydroxylation, and PTH
receptor downregulation as a response to the high preop-
erative PTH level.5–11 Our clinical experience indicates
that ePTH tends to concern referring physicians and
treating surgeons alike.9,12 Furthermore, the natural history
of postoperative ePTH and the optimal testing schedule
 The Author(s) 2011. This article is published with open access
at Springerlink.com
First Received: 24 March 2011;
Published Online: 6 July 2011
B. H.-H. Lang, MS, FRACS
e-mail: blang@hku.hk
Ann Surg Oncol (2012) 19:584–590
DOI 10.1245/s10434-011-1846-5
following parathyroidectomy remains not entirely defined.5
More importantly, some authors have suggested that perhaps
ePTH may imply ‘‘incomplete’’ parathyroidectomy or an
early sign of future HPT recurrence.11,12 This issue is par-
ticularly relevant when an increasing number of surgeons are
now performing focused or limited parathyroidectomy.
Several studies so far have observed that when compared
with patients with eucalcemic normal PTH level, patients
with ePTH are at significantly higher rate of recurrence.9,12
Furthermore, it was found that 1-week serum calcium levels
C9.7 mg/dL and a persistent PTH elevation predicted future
recurrence.9 As a result, our study aimed to examine the risk
factors, the trend of postoperative PTH level, and the long-
term outcome in patients with ePTH 6 months after para-
thyroidectomy for pHPT by comparing perioperative
variables and outcomes between pHPT patients with and
without ePTH at 6-month after parathyroidectomy.
PATIENTS AND METHODS
From 2004–2009, a total of 193 consecutive pHPT
patients were managed at our institution. All were operated
on and managed by the same team of surgeons. Of these, 16
(8.3%) were either lost to follow-up or had less than
6 months of follow-up, 3 (1.6%) had persistent disease, 6
(3.1%) patients had familial HPT or multiple endocrine
neoplasia (MEN), and 7 (3.6%) patients required cal-
cium ± vitamin D supplement for[6 months after surgery.
For the purpose of the study, they were excluded leaving
161 (83.4%) patients eligible for the analysis. The mean
follow-up period was 38.7 ± 23.7 months. An ePTH was
defined as elevated PTH (i.e., [54 pg/mL) in combination
with normal adjusted calcium (Ca) (i.e., B2.55 mmol/L) at
6 months after surgery. At 6-month follow-up, there were
98 (60.9%) with eucalcemic normal PTH (group A) and 63
(39.1%) with ePTH (group B). Demographics, biochemical
profile, operative findings, and postoperative outcomes
were compared between the 2 groups.
Surgical Procedure
Details on the surgical management of pHPT were
described previously.4 Patients with 1 unequivocal preop-
erative localization study by Tc-99m-Sestamibi (MIBI)
scan and/or high-frequency ultrasonography were eligible
for focused or unilateral neck exploration. The focused or
unilateral neck exploration was carried out by making a
2.5-cm lateral skin incision under general or regional cer-
vical block with intravenous sedation. Quick intraoperative
parathyroid hormone assay (IOPTH) and fasting 25-hy-
doxyvitamin D3 (25OHD3) were obtained by peripheral
venous sampling on induction of anesthesia (i.e., before
skin incision). IOPTH was repeated at 0 and 10 min after
adenoma excision. A decline in IOPTH [ 50% at 10 min
compared with that at either induction or 0 min was defined
as biochemical cure.
Laboratory Methods
All measurement of Ca, phosphate, alkaline phospha-
tase, and creatinine levels were measured in the same
laboratory by standardized methods using the Roche
Diagnostics Modular Analytic System (Roche Diagnostics,
Indianapolis, IN).13 Serum 25OHD3 was measured using a
direct electrochemiluminescence immunoassay procedure
(Roche Hitachi Elecsys 2010, Minato-ku, Tokyo, Japan),
and the interassay and intraassay coefficients of variations
(CVs) were 6.6 and 4.0%, respectively. IOPTH was mea-
sured by Access 2 immunoassay system (Beckman Coulter,
Brea, CA) and the interassay and intraassay CVs were
5.8% and 4.5%, respectively. Bone mineral density (BMD)
was measured by the DXA technique using the Hologic
QDR 4500 and Delphi W (Hologic, Bedford, MA).
Follow-up Evaluation
Postoperative serum Ca was measured on Day 0, Day 1,
at 3 months, 6 months, 12 months, and annually, and PTH
level was measured on Day 1, at 3 months, 6 months,
12 months, and annually. Those with hypocalcemic
symptoms and/or a serum Ca \ 2.00 mmol/L were given
2500 mg Oscal tablets twice daily. Rocaltrol 0.25 mcg
twice daily was added if Oscal tablets alone failed to
maintain normocalcemia. Postoperative serum 25OHD3
was not routinely checked. Biochemical cure was defined
as a sustained reduction in serum Ca to a normal level (i.e.,
B2.55 mmol/L) at the latest follow-up, whereas biochem-
ical recurrence was defined as normocalcemia for at least
6 months after surgery, followed by hypercalcemia
(adjusted Ca [ 2.55 mmol/L) some time thereafter. The
present study protocol was approved by the local institu-
tional review board.
Statistical Analysis
Statistical analysis was performed by chi-square or
Fisher exact test to compare categorical variables, and
Mann-Whitney U test was used to compare continuous
variables between groups. Continuous variables were
expressed as mean ± SD. Since there were 63 patients
with ePTH at 6 months and using the rule of thumb of 10
events per covariate, the 5 most statistically significant
covariates (based on lowest P values) in the univariate
analysis were entered into multivariable analysis. Two
binary logistic regression analyses with a variable entrance
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criterion \.05 were conducted to identify preoperative
and operative/postoperative factors associated with ePTH
6 months after surgery, respectively. To evaluate the
changes in postoperative PTH levels over time within each
group, the Wilcoxon paired-sample rank test was used. All
statistical analyses were performed using SPSS version
18.0 (SPSS, Inc., Chicago, IL).
RESULTS
Table 1 shows a comparison of patient demographics,
preoperative biochemical profile, and BMD between groups
A and B. Group B was significantly older at the time of
parathyroidectomy (P = .003), had higher preoperative Ca
(P = .020), higher PTH (P \ .001), higher creatinine levels
(P = .015), and lower 25OHD3 (P = .007) levels than
group A. However, preoperative serum alkaline phospha-
tase and 24-hour urine calcium daily excretion were similar
between the 2 groups. Of the 137 patients (85.1%) who had
BMD measured\4 months before surgery, the BMD at the
forearm, femoral neck, and lumbar spine were significantly
lower in group B than in A.
Table 2 shows a comparison of operative findings
between groups A and B. Group B had significantly
heavier mean total parathyroid tissue excised (1467.5 ±
1946.0 mg vs 937.5 ± 2113.9 mg, P \ .001) and adenoma
(1461.1 ± 1947.9 mg vs 924.4 ± 2118.2 mg, P \ .001)
than group A. Although group B had significantly more
focused or unilateral parathyroid exploration (92.1% vs
79.6%, P = .044), the number of parathyroid glands
excised and total operating time were similar in the 2
groups. Consistent with the higher preoperative PTH level,
the IOPTH level at induction, 0 min, and 10 min after
excision of abnormal parathyroid tissue were also signifi-
cantly higher in group B than in A. However, the
percentage drop in IOPTH at 10 minutes from its highest
level was not different between the 2 groups (P = .412).
Table 3 shows a comparison of postoperative PTH, Ca
levels, follow-up period, and recurrence rate between
groups A and B. A total of 21 patients (21.4%) in group A
and 14 patients (22.2%) in group B had undetectable PTH
level (B 3.0 pg/mL) on postoperative Day 1, and this was
not significantly different between the 2 groups (P = .848).
Although the postoperative mean PTH level on Day 1 was
similar between the 2 groups, the mean PTH level at 3, 6,
12, and 24 months, and latest follow-up were significantly
higher in group B than in A. Postoperative Day 0 and Day
1 Ca were significantly higher in group B than in A.
However, the proportion of patients requiring oral
Oscal ± rocaltrol supplements was similar between groups
B and A (4.8% vs 7.1%, P = .741, respectively). The mean
duration of supplementation for groups B and A was
2.2 ± 1.4 and 2.9 ± 1.5 months, respectively. Of these 10
patients (6.2%), the mean duration of supplementation was
2.7 ± 1.5 months and 4 patients required rocaltrol sup-
plements. The mean follow-up period was similar in groups
A and B (P = .318). One patient in group A and B suffered
biochemical recurrence at 24.2 and 46.7 months, respec-
tively. Recurrence rate was not significantly different
between the 2 groups (1.0% vs 1.6%, P = 1.000).
Figure 1 shows the change in mean postoperative PTH
level on Day 1, at 3 months, 6 months, 12 months, and
2 years after parathyroidectomy in group A and B. In both
groups, there was a significant rise in PTH from postop-
erative Day 1 to 3 months. However, after 6 months, there
were no significant changes in PTH in group A, whereas
there was a significant drop in group B. Postoperative PTH
TABLE 1 Comparison of
patient demographics,
preoperative biochemical
profile, and bone mineral
density between those who had
normal PTH level 6 months
after parathyroidectomy (group
A) and those who had elevated
PTH 6 months after
parathyroidectomy (group B)
PTH parathyroid hormone,
25OHD3 25-hydroxyvitamin D3
a Available in 121 patients
b Available in 137 patients
Group A (n = 98) Group B (n = 63) P value
Age of parathyroidectomy (years) 59.0 ± 13.1 65.6 ± 13.8 .003
Sex .949
Male 26 (26.5) 17 (27.0)
Female 72 (75.5) 46 (73.0)
Body mass index (kg/m2) 24.8 ± 4.9 23.4 ± 3.7 .388
Preoperative adjusted calcium level (mmol/L) 2.86 ± 0.2 2.94 ± 0.3 .020
Preoperative PTH level (pg/mL) 169.3 ± 257.9 249.5 ± 302.6 \.001
Preoperative creatinine level (umol/L) 82.0 ± 24.9 103.9 ± 59.9 .015
Preoperative serum alkaline phosphatase (U/L) 112.8 ± 69.4 116.8 ± 78.1 .898
Preoperative 24-h urine calcium (mmol/day) 6.7 ± 3.7 5.7 ± 3.4 .150
Preoperative 25OHD3 (ng/mL)
a 29.9 ± 18.1 22.2 ± 13.7 .007
Preoperative bone mineral densityb
Forearm (g/cm2) 0.6 ± 0.1 0.5 ± 0.1 .024
Femoral neck (g/cm2) 0.6 ± 0.1 0.6 ± 0.1 .040
L1–4 lumbar spine (g/cm2) 0.8 ± 0.2 0.8 ± 0.2 .040
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elevation appeared to peak at 3–6 months in group B. In
the first 2 postoperative years, only 78 patients (48.4%)
maintained normal postoperative PTH levels over the
entire cohort. Also, 75 patients (46.6%) had elevated PTH
level on at least 1 occasion and 8 (5.0%) had persistently
elevated PTH on all occasions. On further analysis, in
group B, 26 of 55 patients (47.3%) showed a normalized
PTH at 12 months, while in group A, 10 of 86 patients
(11.6%) had an elevated PTH at 12 months. Overall, the
proportion of patients with normalized PTH increased from
62.5% at 6 months to 78.7% at 2 years, although at 2 years
the difference in PTH level was still significant between the
2 groups.
Table 4 shows the multivariable analysis of the 5 most
statistically significant preoperative and perioperative risk
factors for ePTH 6 months after parathyroidectomy. Ade-
noma weight (instead of total parathyroid weight) was
entered into the multivariable analysis. After adjusting for
preoperative PTH, creatinine level and adenoma weight,
advanced age (odds ratio [OR] = 1.042) and low 25OHD3
(OR = 1.043) were independent preoperative factors for
ePTH 6 months after surgery.
Table 5 shows the multivariable analysis of the 5 most
statistically significant operative and postoperative risk
factors for ePTH 6 months after parathyroidectomy. Factors
beyond the 6-month mark were not considered in the model
and only the 10-minute IOPTH was entered instead of all 3
measurements. After adjusting for surgical approach, post-
operative Day 0 Ca level and postoperative Day 1 Ca level,
high 10-minute IOPTH level (OR = 1.015), and high
TABLE 2 Comparison of
operative findings between
those who had normal PTH
level 6 months after
parathyroidectomy (group A)
and those who had elevated
PTH 6 months after
parathyroidectomy (group B)
IOPTH quick intraoperative
parathyroid hormone level
Group A (n = 98) Group B (n = 63) P value
Total parathyroid tissue excised (mg) 937.5 ± 2113.9 1467.5 ± 1946.0 \.001
Weight of adenoma (mg) 924.4 ± 2118.2 1461.1 ± 1947.9 \.001
Operating time (minutes) 74.6 ± 33.8 65.3 ± 30.0 .076
Surgical approach .044
Focused/unilateral 78 (79.6%) 58 (92.1%)
Bilateral exploration 20 (20.4%) 5 (7.9%)
No. of parathyroid glands excised .285
1 86 (87.8%) 59 (93.7%)
C2 12 (12.2%) 4 (6.3%)
IOPTH (pg/mL)
Induction/preincision 124.2 ± 127.5 205.3 ± 287.5 \.001
0 min after excision 64.6 ± 73.4 146.5 ± 225.7 .001
10 min after excision 26.3 ± 21.4 73.0 ± 139.0 \.001
Drop at 10 min (%) 75.0 ± 14.8 69.7 ± 21.9 .412
TABLE 3 Comparison of
postoperative parathyroid
hormone, adjusted calcium
levels, follow-up period, and
recurrence rate between those
who had normal PTH level
6 months after
parathyroidectomy (group A)
and those who had elevated
PTH 6 months after
parathyroidectomy (group B)
PTH parathyroid hormone,
Ca adjusted Ca
* P value \ .05 when compared
with the relative postoperative
6-month PTH
? P value [ .05 when
compared with the relative
postoperative 6-month PTH
Group A (n = 98) Group B (n = 63) P value
Postoperative Day 1 PTH (pg/mL) 19.7 ± 15.3* 34.7 ± 73.8* .795
Postoperative 3-month PTH (pg/mL) 40.2 ± 21.0? 91.1 ± 75.8? \.001
Postoperative 6-month PTH (pg/mL) 35.6 ± 13.3 90.1 ± 46.3 \.001
Postoperative 12-month PTH (pg/mL) 40.1 ± 16.9* 75.1 ± 53.1* \.001
Postoperative 24-month PTH (pg/mL) 39.3 ± 19.0? 69.4 ± 48.4* \.001
Latest postoperative PTH level (pg/mL) 38.6 ± 20.5? 67.8 ± 49.9* \.001
Postoperative Day 0 Ca level (mmol/L) 2.56 ± 0.2 2.64 ± 0.2 .011
Postoperative Day 1 Ca level (mmol/L) 2.35 ± 0.2 2.42 ± 0.2 .021
No. of patients requiring oral Oscal ± Rocaltrol
supplements on discharge
7 (7.1) 3 (4.8) .741
Latest postoperative serum Ca level (mmol/L) 2.25 ± 0.1 2.25 ± 0.1 .486
Drop in serum Ca from the highest preoperative
level to 6-month postoperative level (%)
19.1 ± 6.7 20.9 ± 7.5 .107
Follow-up period (months) 39.9 ± 24.4 36.7 ± 22.6 .318
Biochemical recurrence (%) 1 (1.0) 1 (1.6) 1.000
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postoperative 3-month PTH (OR = 1.048) were indepen-
dent postoperative factors for ePTH 6 months after surgery
DISCUSSION
Despite the fact that the exact etiology remains poorly
understood, the phenomenon of postoperative ePTH in
pHPT has been extensively described and studied.6–12,14–18
In the literature, the reported incidence ranges between
10% and 60%, depending on patient selection and defini-
tion of ePTH.5–12 Unlike previous studies that defined
ePTH as an elevated PTH within weeks after surgery, our
study defined ePTH as an elevated PTH level 6 months
after surgery. This was because surgical cure or success of
parathyroidectomy in pHPT often depends on attaining
normocalcemia at 6 months, and in practice both surgeons
and/or endocrinologists often check Ca and PTH around
this time period.4,13 In our series, the incidence of eu-
calcemic PTH elevation at 6 months was 39.1%, and this
appeared consistent to those previously reported.6–11,14–17
Similar to other studies, although postoperative PTH tends
to slowly normalize over time, it also fluctuates.7,12 Over
the first 2 years, only 78 patients (48.4%) maintained
normal PTH levels throughout the entire cohort. Also, 75
patients (46.6%) had elevated PTH level on at least 1
occasion and 8 (5.0%) had persistently elevated PTH on all
occasions. On closer analysis, in group B, 26 of 55 patients
(47.3%) showed a normalized PTH at 12 months, while in
group A, 10 of 86 patients (11.6%) had an elevated PTH at
12 months.
To examine the possible relationship between perioper-
ative factors and ePTH at 6 months, two binary regression
analyses were performed; one for preoperative factors and
the other for operative/postoperative factors. In the uni-
variate analysis of preoperative factors, similar to previous
studies, advanced age, higher PTH, higher creatinine, hea-
vier adenoma, and low 25OHD3 were significantly
associated with ePTH; in the multivariable analysis,
advanced age and low 25OHD3 were factors independently
associated with ePTH at 6 months.7–9,11,12,17,18 Although
age and 25OHD3 would seem interrelated as the latter tends
to decrease with age, our data seemed to support the
hypothesis that preexisting vitamin D deficiency is a pos-
sible cause of postoperative ePTH. This is consistent with
previous studies.7,13,19,20 The implication is that perhaps
patients with advanced age or with low preoperative
25OHD3 may benefit from a course of vitamin D supple-
mentation after surgery. Beyer et al. reported that by giving
0.25 mcg oral rocaltrol supplementation after parathyroid-
ectomy, the incidence of postoperative ePTH was
significantly decreased compared with those who received
oral calcium alone.15 However, it was interesting that
Grubbs et al. demonstrated that giving ergocalciferol for
a median duration of 28 days before parathyroidectomy
did not correct postoperative ePTH.21 That means that if
postoperative ePTH is to be corrected by vitamin D sup-
plementation, it should be administered for some time after
surgery, although the optimal duration remains unknown.
To further confirm these findings, perhaps measuring
postoperative 25OHD3 level in both groups would be use-
ful, but such data were not available in our study. The
authors believed this would definitely be an area for future
studies. When both operative and postoperative factors
were analyzed in the univariate and multivariable analyses,
high 10-min IOPTH and high postoperative 3-month PTH
level were independently associated with ePTH. However,
given the nature of these factors, they probably acted as
surrogates rather than risk factors for ePTH. Nevertheless,
they would be useful indicators for possible ePTH in the
future.
In terms of etiology, although the vitamin D deficiency
hypothesis remains the most plausible mechanism for
postoperative ePTH, other hypotheses including a multi-
factorial model are still possible given the interrelationship
of these factors. For example, the finding of lower preop-
erative BMD at the forearm, femoral neck, and lumbar
spine in group B seems to support the hungry bone syn-
drome hypothesis as more severe bone mineral loss leads to
more severe bone hunger and higher PTH. However, unlike
previous studies, our study did not observe the higher level
FIG. 1 Change in mean postoperative serum parathyroid hormone
(PTH) level on Day 1, at 3 months, 6 months, 12 months, and 2 years
after parathyroidectomy in those with normal PTH level at 6 months
(group A) and those with elevated PTH at 6 months (group B); blue
line represents group A (n = 98); yellow line represents group B
(n = 63)
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of alkaline phosphatase that is a marker for bone turnover
in group B.9,17,22 Perhaps, a future study could assess other
bone markers such as osteocalcin and propeptide type I
collagen to see if they also remain similar in the 2 groups.
Although BMD improves after parathyroidectomy, it is
unclear whether similar improvement is observed in those
with and without ePTH.23 Although the higher creatinine
level or worse renal impairment is one particular state in
which PTH resistance is frequently observed, our study
was unable to establish whether the PTH elevation was
specifically related to PTH resistance.24 Perhaps, measur-
ing the level of nephrogenous cyclic adenosine
monophosphate or the 1,25-dihyroxyvitamin D/PTH ratios
would shed light on this issue.7,8
In terms of operative findings, it was somewhat expected
to find that patients with ePTH were significantly more
likely to undergo focused or unilateral exploration because
heavier adenoma is generally more likely to localize
unequivocally.4 In contrast to one previous study that
found a less significant drop of PTH in the elevated PTH
group, our data showed the percentage drop was similar in
the 2 groups.18
There have been suggestions that perhaps ePTH after
parathyroidectomy may imply a ‘‘less complete’’ parathy-
roidectomy.9,11,12 Siperstein et al. showed that preoperative
localizing studies and IOPTH failed to identify multiglan-
dular disease (MGD) in at least 16% of pHPT patients.25
One postulation is that perhaps those with ePTH may suffer
from undiagnosed MGD. However, so far, our data do not
support this. After a mean follow-up of 38.7 months, the
recurrence rate appeared similar in the 2 groups, although
the number of recurrences was small and longer follow-up
period might have been necessary.
In terms of the trend of ePTH, our study found the ePTH
peaked sometime between 3 and 6 months. This differs
from one study which observed the peak occurring at
2 months.17 However, similar to previous reports, the trend
of PTH slowly normalized over time in patients with ePTH
with more than 3/4 of the entire cohort having normal
PTH.6,10,12,14 Future studies could focus on which factors
influence the duration of normalization. One obvious factor
would be vitamin D supplementation.15 However, since
only 6.2% of patients received vitamin D supplementation
lasting a mean duration of 2.7 ± 1.5 months, we did not
exclude them from the binary logistic regression model.
The authors believe that the trend of PTH may represent the
trend of postoperative PTH in an untreated vitamin D group.
Despite our findings, our data should be interpreted
cautiously as there were limitations. Firstly, because of the
retrospective nature, some preoperative variables such as
25OHD3 and BMD as well as postoperative PTH levels
were incomplete, and this limits the power of the multi-
variable analysis. Secondly, because of the relatively short
follow-up, our data only had 2 patients with recurrence,
and that limits the power of the study. Our data came from
one university hospital and so were subjected to both
institutional and referral biases. Future studies could assess
the association between ePTH and other outcome variables
such as quality of life, BMD, or fracture risk.
In conclusion, advanced age (OR = 1.042, P = .027)
and low 25-OHD3 (OR = 1.043, P = .009) were inde-
pendent preoperative factors associated with ePTH,
TABLE 4 A multivariable
analysis of preoperative and
perioperative factors for
eucalcemic parathyroid
hormone elevation 6 months
after parathyroidectomy
PTH parathyroid hormone,
25OHD3 25-hydroxyvitamin D3
Covariates b coefficient Odds ratios
(95% confidence interval)
P value
Age of parathyroidectomy (years) (n = 161) 0.041 1.042 (1.005–1.080) .027
Preoperative PTH level (pg/mL) (n = 161) 0.001 1.001 (0.998–1.003) .646
Preoperative creatinine level (umol/L) (n = 161) 0.012 1.013 (0.999–1.026) .071
Adenoma weight (mg) (n = 161) 0.001 1.000 (0.999–1.001) .099
Preoperative 25OHD3 (ng/mL) (n = 121) 0.042 1.043 (1.010–1.076) .009
TABLE 5 Multivariable
analysis of operative and
postoperative factors for
eucalcemic parathyroid
hormone elevation 6 months
after parathyroidectomy
IOPTH quick intraoperative
PTH level, PTH parathyroid
hormone, Ca adjusted serum
calcium
Covariates b coefficient Odds ratios
(95% confidence interval)
P value
Unilateral neck exploration (n = 161) -0.006 0.994 (0.278–3.557) .992
IOPTH 10-min after excision (pg/mL)
(n = 161)
0.015 1.015 (1.001–1.029) .040
Postoperative 3-month PTH level (pg/mL)
(n = 161)
0.048 1.048 (1.028–1.069) \.001
Postoperative Day 0 Ca level (n = 161) 1.873 6.508 (0.189–224.0) .300
Postoperative Day 1 Ca level (mmol/L)
(n = 161)
3.339 8.329 (0.273–3.557) .224
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whereas high 10-minute intraoperative PTH level (OR =
1.015, P = .040) and high postoperative 3-month PTH
(OR = 1.048, P \ .001) were independent postoperative
factors associated with ePTH at 6 months. Given these
findings, perhaps patients with these factors could receive a
postoperative course of vitamin D supplementation in an
attempt to normalize ePTH. However, the optimal duration
remains unknown and is an area for further study. In
addition, our data showed that in the first 2 postoperative
years, more than half had elevated PTH level on at least
one occasion and 8 (5.0%) had persistently elevated
PTH level on all occasions. After a mean follow-up of
38.7 months, recurrence rate appeared similar between
those with ePTH and without ePTH at 6 months.
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